---
layout: post
title: "Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 18:56:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-16775
original_published: 2023-08-07 00:00:00 +0000
significance: 8.00
---

# Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 07, 2023 00:00 UTC
**Document Number:** 2023-16775

## Summary

The Food and Drug Administration (FDA or Agency) has determined that CUBICIN (daptomycin) Powder for Injection, 250 milligrams (mg)/vial and 500 mg/vial, and CUBICIN RF (daptomycin) Powder for Injection, 500 mg/vial, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for daptomycin powder for injection, 250 mg/vial and 500 mg/vial, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/07/2023-16775/determination-that-cubicin-daptomycin-powder-for-injection-250-milligramsvial-and-500-milligramsvial)
- API: https://www.federalregister.gov/api/v1/documents/2023-16775

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
